Equity Overview
Price & Market Data
Price: $2.60
Daily Change: -$0.28 / 10.77%
Daily Range: $2.45 - $3.00
Market Cap: $1,613,656,832
Daily Volume: 2,764,425
Performance Metrics
1 Week: -7.40%
1 Month: -40.90%
3 Months: 300.6%
6 Months: 53.59%
1 Year: 42.50%
YTD: 51.78%
Company Details
Employees: 204
Sector: Health technology
Industry: Biotechnology
Country:
Details
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.